Introduction: The appreciable growth in pharmaceutical expenditure has resulted in multiple initiatives across Europe to lower generic prices and enhance their utilisation. However, considerable variation in their use and...
Background: There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are effectiveness, safety and/ or budget concerns. Dabigatran, a new oral anticoagulant for...
Sieghard Beller, Andrea Bender and Michael Waldmann
August 15, 2014
University of Turin
Frontiers Review Editor
Michigan State University
East Lansing, USA
© 2007 -
Frontiers Media S.A. All Rights Reserved